Skip to Content
Merck
CN
  • Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency.

Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency.

Journal of Korean medical science (2012-05-09)
Dae Eun Choi, Kang Wook Lee, Young Tai Shin, Ki Ryang Na
ABSTRACT

Ornithine carbamoyltransferase (OTC) deficiency is a urea cycle disorder that causes the accumulation of ammonia, which can lead to encephalopathy. Adults presenting with hyperammonemia who are subsequently diagnosed with urea cycle disorders are rare. Herein, we report a case of a late-onset OTC deficient patient who was successfully treated with arginine, benzoate and hemodialysis. A 59-yr-old man was admitted to our hospital with progressive lethargy and confusion. Although hyperammonemia was suspected as the cause of the patient's mental changes, there was no evidence of chronic liver disease. A plasma amino acid and urine organic acid analysis revealed OTC deficiency. Despite the administration of a lactulose enema, the patient's serum ammonia level increased and he remained confused, leading us to initiate acute hemodialysis. After treatment with arginine, sodium benzoate and hemodialysis, the patient's serum ammonia level stabilized and his mental status returned to normal.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium benzoate, puriss., meets analytical specification of Ph. Eur., BP, FCC, E211, 99.0-100.5% (calc. to the dried substance), powder
Sigma-Aldrich
Sodium benzoate, purum p.a., ≥99.0% (NT)
Supelco
Sodium benzoate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sodium benzoate, BioXtra, ≥99.5%
Sigma-Aldrich
Sodium benzoate, ReagentPlus®, 99%